Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Observational Study of Electrical Impedance Tomography for Non-Invasive Assessment of Cerebral Autoregulation in Neurocritical Patients

24 maj 2026 uppdaterad av: Xijing Hospital

A Clinical Study of Non-Invasive Assessment of Cerebral Autoregulation Using Electrical Impedance Tomography

This is a single-center, prospective, observational, self-controlled clinical study conducted at the Neurosurgical Intensive Care Unit of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study aims to evaluate whether non-invasive Electrical Impedance Tomography (EIT) can reliably assess cerebral blood flow autoregulation in neurocritically ill participants, by comparing EIT-derived parameters with the current gold-standard invasive index PRx.

Cerebral blood flow autoregulation helps maintain stable brain perfusion in critically ill neurological patients. Impaired autoregulation raises the risk of secondary brain injury. The current standard evaluation requires invasive intracranial pressure monitoring, which carries risks of infection, bleeding, and tissue damage. EIT is a non-invasive, radiation-free bedside monitoring technique that uses scalp electrodes to measure real-time changes related to cerebral blood flow, with no additional harm to participants.

Adult participants admitted to the neurosurgical intensive care unit who require routine invasive intracranial pressure monitoring will be enrolled, with informed consent provided by legal guardians. All participants receive standard clinical care as prescribed by current medical guidelines; no extra experimental treatments, drugs, or invasive procedures are applied for this study.

During the study, invasive monitoring data and non-invasive EIT brain monitoring data will be collected simultaneously. Researchers will analyze the correlation and consistency between EIT-derived parameters and the gold-standard index.

This study has received ethical approval from the Medical Ethics Committee of The First Affiliated Hospital, Air Force Military Medical University. All participant information is anonymized to protect privacy, and adverse events will be recorded and reported in accordance with regulatory requirements. The results are expected to support a safe, non-invasive monitoring method for cerebral blood flow autoregulation in neurocritical care.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Detaljerad beskrivning

Background and Rationale Cerebral autoregulation (CA) is the ability of the cerebrovascular system to maintain relatively constant cerebral blood flow when cerebral perfusion pressure is extremely high or low. In neurocritical patients with acute intracerebral hemorrhage, subarachnoid hemorrhage, or ischemic stroke, impaired CA is closely associated with secondary brain injury, intracranial hypertension, neurological deterioration, and poor outcomes. The pressure reactivity index (PRx), calculated as the moving Pearson correlation between invasively measured intracranial pressure (ICP) and mean arterial pressure (MAP), is the current gold standard for bedside assessment of CA. However, invasive ICP monitoring requires surgical placement of an intraventricular or intraparenchymal catheter, which carries risks of infection, hemorrhage, cerebrospinal fluid leakage, and tissue damage, and requires specialized expertise and intensive care resources, limiting widespread use.

Electrical impedance tomography (EIT) is a non-invasive, radiation-free, real-time biomedical imaging technique that measures regional changes in bioimpedance, which reflect variations in cerebral blood volume and tissue perfusion. A custom-built cerebral EIT system (EC100-PRO) has been developed by the research team. It uses 16 scalp electrodes placed in a ring configuration to continuously acquire impedance signals. Through standardized signal processing and image reconstruction algorithms, EIT-derived parameters that track cardiac-synchronous cerebral blood volume pulsations are generated. Preclinical and pilot clinical data indicate that these EIT-derived parameters correlate with changes in cerebral perfusion and autoregulatory status. This study aims to validate the agreement between EIT-derived parameters and the reference standard PRx, thereby establishing a non-invasive, continuous alternative for CA monitoring in neurocritical care.

Study Design and Technical Framework This is a single-center, prospective, observational, self-controlled clinical study conducted in the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study is observational: EIT monitoring serves only as an additional non-invasive signal acquisition and does not interfere with, terminate, or affect the patient's original clinical diagnosis and treatment plan. It is self-controlled because invasive ICP/ABP data and non-invasive EIT data are collected synchronously from the same patient, using the patient's own invasive standard (PRx) to verify the accuracy of the non-invasive index.

All participants receive standard clinical care according to current international neurocritical care guidelines (including blood pressure management per the 2024 Chinese Expert Consensus on Hypertension Management in Stroke Patients, sedation, analgesia, and ICP-directed therapy). No experimental drugs, additional surgical procedures, or treatment modifications are applied for research purposes. EIT monitoring is add-on only and does not interrupt routine care.

Continuous synchronous multimodal data acquisition is performed during the participant's NICU stay. Invasive MAP (via femoral arterial catheter) and ICP (via intraventricular catheter) are measured as standard of care. The EIT system applies a 1 mA, 50 kHz alternating current through 16 Ag/AgCl electrodes placed equidistantly around the scalp at the level of the upper border of the eyebrow arch to the external occipital protuberance. Electrode-skin impedance is kept below 5 kΩ. EIT data are acquired at 40 frames per second.

Signal preprocessing includes low-pass filtering at 0.05 Hz to remove respiratory and high-frequency artifacts and resampling to 10-second averages. The reference index PRx is calculated as the Pearson correlation between MAP and ICP within a 300-second sliding window (step 60 seconds). From the EIT image sequence, a parameter reflecting cardiac-synchronous cerebral blood volume pulsation is extracted. Within the same 300-second sliding window, the correlation between MAP and this EIT-derived parameter (called the EIT-CA index) is computed. Data segments with electrode contact impedance >5 kΩ or motion artifacts exceeding 10% of the recording duration are excluded. At least 2 hours of continuous valid data per participant are required for analysis.

Study Design and Technical Framework This is a single-center, prospective, observational, self-controlled clinical study conducted in the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, The First Affiliated Hospital of Air Force Military Medical University. The study is observational: EIT monitoring serves only as an additional non-invasive signal acquisition and does not interfere with, terminate, or affect the patient's original clinical diagnosis and treatment plan. It is self-controlled because invasive ICP/ABP data and non-invasive EIT data are collected synchronously from the same patient, using the patient's own invasive standard (PRx) to verify the accuracy of the non-invasive index.

All participants receive standard clinical care according to current international neurocritical care guidelines (including blood pressure management per the 2024 Chinese Expert Consensus on Hypertension Management in Stroke Patients, sedation, analgesia, and ICP-directed therapy). No experimental drugs, additional surgical procedures, or treatment modifications are applied for research purposes. EIT monitoring is add-on only and does not interrupt routine care.

Continuous synchronous multimodal data acquisition is performed during the participant's NICU stay. Invasive MAP (via femoral arterial catheter) and ICP (via intraventricular catheter) are measured as standard of care. The EIT system applies a 1 mA, 50 kHz alternating current through 16 Ag/AgCl electrodes placed equidistantly around the scalp at the level of the upper border of the eyebrow arch to the external occipital protuberance. Electrode-skin impedance is kept below 5 kΩ. EIT data are acquired at 40 frames per second.

Signal preprocessing includes low-pass filtering at 0.05 Hz to remove respiratory and high-frequency artifacts and resampling to 10-second averages. The reference index PRx is calculated as the Pearson correlation between MAP and ICP within a 300-second sliding window (step 60 seconds). From the EIT image sequence, a parameter reflecting cardiac-synchronous cerebral blood volume pulsation is extracted. Within the same 300-second sliding window, the correlation between MAP and this EIT-derived parameter (called the EIT-CA index) is computed. Data segments with electrode contact impedance >5 kΩ or motion artifacts exceeding 10% of the recording duration are excluded. At least 2 hours of continuous valid data per participant are required for analysis.

Studietyp

Observationell

Inskrivning (Beräknad)

100

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study population consists of adult neurocritical care inpatients admitted to the Neurosurgical Intensive Care Unit (NICU) of Xijing Hospital, the First Affiliated Hospital of Air Force Military Medical University. Eligible participants are patients aged ≥18 years with severe acute cerebrovascular diseases, severe traumatic brain injury and other critical central nervous system disorders who require NICU admission and routine invasive intracranial pressure and mean arterial pressure monitoring, forming a single-center prospective observational cohort with consecutive enrollment.

Beskrivning

Inclusion Criteria:

  • Aged ≥18 years old
  • Diagnosed with acute intracerebral hemorrhage, subarachnoid hemorrhage or ischemic stroke, admitted to the Neurosurgical Intensive Care Unit
  • Receiving routine invasive monitoring of intracranial pressure (ICP) and mean arterial pressure (MAP)
  • Written informed consent obtained from the legally authorized representative

Exclusion Criteria:

  • Severe scalp damage, infection or skull defect affecting electrode placement
  • Craniotomy history with metal implants interfering with EIT signal acquisition Pregnancy
  • Terminal critical illness with estimated survival <24 hours
  • Severe coagulation dysfunction or confirmed allergy to electrode materials
  • Unavailable for ≥2-hour continuous valid monitoring data collection

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Correlation and consistency between EIT-derived parameters and pressure reactivity index (PRx) for cerebral blood flow autoregulation assessment
Tidsram: Through study completion, an average of 1 year
To evaluate the linear correlation (Pearson correlation coefficient) and agreement (Bland-Altman analysis) between non-invasive EIT-derived parameters and the invasive gold-standard PRx index in assessing cerebral blood flow autoregulation among neurocritically ill patients.
Through study completion, an average of 1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

30 maj 2026

Primärt slutförande (Beräknad)

28 februari 2028

Avslutad studie (Beräknad)

30 maj 2028

Studieregistreringsdatum

Först inskickad

17 maj 2026

Först inskickad som uppfyllde QC-kriterierna

17 maj 2026

Första postat (Faktisk)

22 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

28 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • KY20262178-C-1

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data (IPD) will not be shared with external researchers due to privacy protection and institutional data security regulations. Aggregated statistical results will be published in peer-reviewed journals.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera